PROSPER-8
Research type
Research Study
Full title
A prospective single cohort study evaluating clinical efficacy with intravitreal aflibercept 8mg in treatment resistant Polypoidal Choroidal Vasculopathy
IRAS ID
365661
Contact name
Luke Nicholson
Contact email
Sponsor organisation
Moorfields Eye Hospital NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Polypoidal choroidal vasculopathy (PCV) is a form of age‑related macular degeneration that can cause fluid, bleeding, and swelling at the back of the eye. Many people with PCV need frequent anti‑VEGF injections, and some continue to have active disease despite regular treatment.
Aflibercept 8 mg (Eylea HD) is a higher‑dose version of an established treatment for macular disease. Early studies suggest it may control PCV more effectively, especially in patients whose disease remains active on standard treatment.
This study will follow 70 participants receiving aflibercept 8 mg at Moorfields Eye Hospital. Participants will have eye examinations and scans over 24 weeks to assess whether the treatment reduces disease activity, improves or stabilises vision, and reduces swelling under the retina. All treatments and tests in this study are part of standard NHS eye care. Taking part is voluntary, and participants can withdraw at any time without affecting their usual care.
The results will help doctors understand whether aflibercept 8 mg offers better control of PCV in patients who do not fully respond to their current injections.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
26/WM/0076
Date of REC Opinion
22 Apr 2026
REC opinion
Favourable Opinion